About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, November 1st, 2017

The QualityStocks
Daily Stock List


Cannabis Sativa, Inc. (CBDS)

Cannabis Financial Network News, Greenbackers, TheMicrocapNews, TopStockAnalysts, Flagler Financial Group, Promotion Stock Secrets, Jason Bond, Marketbeat, TopPennyStockMovers, Stockgoodies, Top Pros’ Top Picks, Insider Financial, Darwin Investing Network, Wall Street Mover, Stock Beast, smartOTC, and Real Pennies reported earlier on Cannabis Sativa, Inc. (CBDS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Cannabis Sativa, Inc. involves in branding and licensing by way of its 'hi' intellectual properties. The Company engages, through its subsidiaries, Wild Earth Naturals and "hi" Brands International, Inc., in the research, development, and licensing of specialized natural products. These include formulas, edibles, topicals, recipes, as well as delivery systems. Cannabis Sativa has been active in pursuing Intellectual Property (IP) and has successfully acquired a growing portfolio of IP. Based in Mesquite, Nevada, Cannabis Sativa’s shares trade on the OTC Markets’ OTCQB.

Cannabis Sativa brands, licenses, innovates, and markets first-rate plant-derived topical creams, transdermals, balms, sublinguals, lubricants, and edibles for medical and recreational marijuana consumers, and legal nutraceuticals and branded merchandise for consumers in general. The Company’s objective is to license the "hi" brand to distributors and producers of quality products and to other ancillary participants in the retail cannabis industry.

Cannabis Sativa has acquired a majority ownership interest in iBudtender, Inc., a Colorado corporation. In addition, it entered into an agreement to acquire a 49 percent ownership interest in a nine-acre property in Los Angeles County, California. The ownership group’s plan is to lease the property to an industrial hemp farm operator. The operator will conduct farming activities under the Industrial Hemp provisions of California's Adult Use Marijuana Act (Prop 64).

Cannabis Sativa has its Wild Earth Naturals offerings. The Company offers the Wild Earth Naturals line of CBD Water and cosmetic products designed to use organic and natural ingredients. These include CBD and hemp seed oil. Cannabis Sativa’s wholly-owned subsidiary, Hi Brands International, entered into an agreement with Centuria Natural Foods, Inc. to market their proprietary CBD Rich Hemp Oil products. Their CBD capsules are marketed under the name, "hi CBD."

Cannabis Sativa has entered into a license agreement for the manufacture, marketing, and sale of its White Rabbit products in California. The Company closed its acquisition of the White Rabbit brand of cannabis sprays and cannabis mints. The acquisition includes the exclusive and proprietary product formulations, product mixes, manufacturing methods, and branding. The White Rabbit product line now consists of fast-acting low dose cannabis oral sprays and low dose cannabis mints. Cannabis Sativa has developed a "hi" branded infused honey product (hi honey) made from rich African honey and infused with CBD or THC.

Cannabis Sativa has acquired a controlling interest in PrestoCorp (a.k.a. PrestoDoctor). This is an online telemedicine platform. It provides access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation utilizing secure video conferencing technology. Appointments via PrestoDoctor's website are usually completed in 10-15 minutes. They can be scheduled and completed in the same day.

PrestoDoctor has greater than 4,000 5-star reviews. It is the first medical marijuana company to be accepted into the American Telemedicine Association. PrestoDoctor is HIPAA and HITECH compliant.

Cannabis Sativa announced in September that it granted an exclusive license to the Sowilde Management Group, Inc. This is to allow Sowilde to produce products under Cannabis Sativa’s "hi" and "White Rabbit" brands. The initial products offered to the market by Sowilde are the White Rabbit line of cannabis sprays and cannabis mints and hi Infused Wild Honey.

Cannabis Sativa, Inc. (CBDS), closed Wednesday's trading session at $2.72, down 1.45%, on 51,826 volume with 158 trades. The average volume for the last 60 days is 51,364 and the stock's 52-week low/high is $2.61/$9.50.

Canarc Resource Corp. (CRCUF)

Baby Bulls, CrushTheStreet, AllPennyStocks, Research Driven Investor, FutureMoneyTrends, FeedBlitz, ShazamStocks, SmallCapVoice, and Stockhouse reported on Canarc Resource Corp. (CRCUF), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Canarc Resource Corp. is a growth-oriented, gold exploration and mining company based in Vancouver, British Columbia. It is presently focusing on acquiring operating or pre-production stage gold-silver-copper mines or properties in the Americas and further advancing its gold properties in north and central British Columbia. Canarc Resource lists on the OTC Markets’ OTCQB.

Canarc’s core Gold Project asset is the 100 percent owned, past-producing, high-grade New Polaris gold mine project in northwestern British Columbia. Based on an updated NI 43-101 resource estimate using a 6 gpt gold cutoff grade, the New Polaris property currently contains measured and indicated resources of 519,000 oz gold contained in 1,288,000 tonnes grading 12.5 gpt gold. New Polaris contains inferred resources totaling 636,000 oz gold contained in 1,628,000 tonnes grading 12.2 gpt gold (still open for expansion in other veins and at depth).

Additionally, the Company has its Windfall Hills gold project. Windfall Hills is 65 kilometers south of Burns Lake and 90 kilometers’ northwest of Richfield Ventures’ Blackwater gold discovery in central British Columbia. The Windfall Hills project encompasses claims totaling 3879 hectares situated within the same geological belt of Tertiary volcanic rocks as Richfield’s Blackwater gold discovery.

Canarc Resource Management remains centered on acquiring near term gold-silver-copper mining assets in Mexico, the United States and Canada. This is together with a renewed effort to advance its New Polaris and Windfall Hills projects.

The Company, after having received regulatory approvals, closed the definitive agreement with Eureka Resources, Inc., pursuant to which Canarc has an exclusive option to acquire up to a 75 percent interest in the FG Gold Property located approximately 100 kilometers east of Williams Lake in central B.C.

Canarc Resource has received approval from the U.S. Bureau of Land Management for a drilling campaign at its Fondaway Canyon property in the State of Nevada. The program comprises 7 core holes totaling 2,700 meters in 5 target areas at depths of up to 400 meters. This program will cost about $850,000 CDN. The Company will fund it from existing cash.

Canarc Resource reported at the end of July that a recently completed surface rock-chip sampling and mapping program at its Fondaway Canyon property in Churchill County, Nevada returned a number of high-grade gold values of greater than 5 gpt Au in multiple zones at surface.

Of the 42 surface rock-chip samples collected in June and July 2017, 5 samples assayed gold values of 10-24 gpt Au, 11 samples returned more than 5 gpt Au, and 25 samples essayed more than 1 gpt Au.

Canarc Resource Corp. (CRCUF), closed Wednesday's trading session at $0.0568, down 3.73%, on 18,000 volume with 2 trades. The average volume for the last 60 days is 38,101 and the stock's 52-week low/high is $0.0466/$0.088.

Kiwa Bio-Tech Products Group Corp. (KWBT)

The Stock Psycho, Top Gun, Penny Stock Rumble, StockMister, The Penny Play, Equities, SmallCapVoice, Wallstreetlivechat, Lions of Wall Street, Fast Moving Stocks, Darth Trader, and OTC Picks reported earlier on Kiwa Bio-Tech Products Group Corp. (KWBT), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Kiwa Bio-Tech Products Group Corporation is a manufacturer concentrating on eco-friendly bio-based fertilizers promoting soil health. The Company develops, manufactures, distributes, and markets novel, cost-effective and environmentally safe bio-technological products for agricultural and environmental conservation. Kiwa Bio-Tech Products Group is based in Claremont, California.

The Company’s commitment is to eco-agricultural development and environmental control through developing, producing, and selling bio-technological products with high technology, low-cost, and high productivity to satisfy growing market demand. Kiwa Bio-Tech’s dedication is to making safe food, further developing eco-agriculture, and upholding a responsibility of contributing to China's agricultural safety, food safety, and a healthy lifestyle.

The design of the Company’s products is to enhance the quality of human life through increasing the value, quality, and productivity of crops and reducing the negative environmental impact of chemicals and other wastes. Kiwa Bio-Tech utilizes new bio-technological skills at its core. Organic, ecologically sound, and "green" practices are its theme.

Kiwa Bio-Tech has a strategic cooperation agreement with the Beijing Zhongpin Agricultural Science and Technology Development Center (Zhongpin Center). Zhongpin Center is the Chinese Agricultural Science and Technology Innovation and Development Committee's executive implementation agency (called the Agricultural Science and Technology Commission).

Through the guidance and support by the Zhongpin Center, Kiwa Bio-Tech will participate and be involved in China's National Soil Remediation Program and construction of the National Ecological Security Agriculture Industrial Chain Standardization System's operation and process.

Kiwa Bio-Tech has launched a joint venture (JV) with Zhongshi'an Agricultural Science & Technology Co., Ltd. and Xintaitianyi Financial Service and Science & Technology Co., Ltd. The name of the JV is Inner Mongolia Jingnong Investment Management Co. Ltd.

Kiwa Bio-Tech is a 40 percent partner in the venture. This venture will have an initial capitalization of roughly $1.5 million. Jingnong will invest in the expansion of Kiwa Bio-Tech’s existing production base in Shandong Province and in the construction of three new manufacturing bases of Kiwa in Inner Mongolia Province, Xinjiang Province, and Guizhou Province.

Recently, Kiwa Bio-Tech announced that it completed a repositioning and updating of its products. This is to meet the diverse market demands for biological organic fertilizers. The Company’s intention is that all of the new updated products will enter into the market next year.

The Company’s new products structure includes 16 types of products in 5 major categories. These categories are Biological Organic Fertilizer, Compound Microorganism Fertilizer, Microorganism Bacterium Agent, Biological Soluble Fertilizer, and Organic-Inorganic Compound Fertilizer.

Kiwa Bio-Tech Products Group Corp. (KWBT), closed Wednesday's trading session at $1.75, down 7.89%, on 1,808 volume with 8 trades. The average volume for the last 60 days is 2,159 and the stock's 52-week low/high is $0.75/$3.57.

Enumeral Biomedical Holdings, Inc. (ENUM)

Marketbeat reported on Enumeral Biomedical Holdings, Inc. (ENUM), and and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enumeral Biomedical Holdings, Inc. is concentrating on the discovery and advancement of next generation therapeutics in cancer, auto-immune, as well as other diseases. It is discovering and developing novel antibody immunotherapies that assist the immune system in attacking diseased cells. The Company is building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and taking advantage of the extensiveness of its technology via strategic collaborations. Enumeral Biomedical Holdings is headquartered in Cambridge, Massachusetts.

Enumeral is enabling and expediting the discovery and development of novel antibody immunotherapies, or immunomodulators, which are validated with its human-driven immune profiling platform. The Company’s immunoprofiling platform harnesses The Power of Human™.

The Company’s unique platform enables it to identify and characterize promising new drugs relevant to cancer, infectious, and inflammatory diseases. The core technology underlying the Company’s platform was developed at, and licensed from, the Massachusetts Institute of Technology (MIT), Harvard University, and Whitehead Institute for Biomedical Research and Massachusetts General Hospital.

Enumeral utilizes a proprietary microwell array technology to identify cell kind and measure functioning of individual cells from tissue samples, and to retrieve individual live cells of interest, for cell culture or gene cloning. This technology provides important insights for target validation, drug candidate selection, and also rational drug development. In addition, Enumeral has built a pipeline of immune checkpoint modulators for targets. These include PD-1, TIM-3, CD39, and others.

Enumeral Biomedical was continuing to pursue its pipeline of antibody candidates. This includes its PD-1 antibody program. It chose one of its lead anti-PD-1 antibody candidates, named ENUM 244C8, for further development.

Enumeral Biomedical Holdings and the International Consortium on Anti-Virals (ICAV) entered into a Memorandum of Understanding (MOU) to pursue an infectious disease collaboration using Enumeral's proprietary platform. The objective of this collaboration is to isolate and characterize high affinity, broadly neutralizing human antibodies against select human pathogens from patients earlier infected or vaccinated for therapeutic intervention, prophylaxis, and/or diagnostic utility.

This past August, Enumeral Biomedical Holdings announced its financial results for the three months ended June 30, 2017. Also, on June 29, 2017, the Company’s Board, having evaluated and pursued a range of potential strategic transactions, and other alternatives for the sale or disposition of its assets on a going concern basis, determined that it is in the best interests of its stockholders and creditors to wind down the Company’s remaining operations and effect an orderly disposition of Enumeral’s remaining assets. This includes Enumeral’s intellectual property (IP) related to its PD-1 and TIM-3 antibody programs.

Enumeral Biomedical Holdings, Inc. (ENUM), closed Wednesday's trading session at $0.0037, down 2.63%, on 1,069,960 volume with 16 trades. The average volume for the last 60 days is 797,109 and the stock's 52-week low/high is $0.0016/$0.2197.

Pharma-Bio Serv, Inc. (PBSV)

Zacks reported previously on Pharma-Bio Serv, Inc. (PBSV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Pharma-Bio Serv, Inc. is a compliance, project management, and technology transfer support consulting firm. The Company’s primary business is Food and Drug Administration (FDA) and other international regulatory compliance agency related services, with integrated portfolio services including microbiological and chemical testing services. This includes microbiological and chemical testing services for clients in the Pharmaceutical, Biotechnology, and Chemical, Medical Device, Cosmetic, Food and Allied Products industries, at its laboratory testing facility in Puerto Rico. Pharma-Bio Serv is based in Dorado, Puerto Rico. The Company also has operations in the U.S., Ireland, and Spain.

Pharma-Bio Serv supports its clients by way of the product lifecycle. This includes research and development (R&D) Studies; NDA Documentation and Filings; PAI Readiness; Audit & Inspection Preparation, Management and Response, and Post Approval. Furthermore, this includes Quality Systems; Technology Transfer; Validation, and Manufacturing Controls & Process Support.

The Company’s worldwide team includes top engineering and life science professionals, quality assurance managers, as well as directors. Also, the Company’s services include "Pharma Serv Academy." This division provides technical and regulatory standards seminars/training conducted by industry experts.

Pharma-Bio Serv’s divisions include Scienza Labs, the abovementioned PharmaServ Academy, and Metrologix. Scienza Labs provides microbiological and analytical testing, field support, method development, and validation. Metrologix provides laboratory and on-site calibration services, calibration program management, risk management, compliance remediation, and instrument rental.

This past September, Pharma-Bio Serv announced Net Revenues for the three and nine months ended July 31, 2017 were $4.0 and $11.9 million, respectively. This represents a decrease of roughly $0.9 and $2.9 million, or 18.2 percent and 19.8 percent, respectively, versus the same periods the year prior.

The decrease for the three months ended July 31, 2017, versus the same period last year, is primarily because of a decline in projects in the Puerto Rico consulting market of $0.9 million. The Company’s other divisions sustained minor revenue gains/losses or remained constant, versus the same period the year prior.

Mr. Victor Sanchez, Pharma-Bio Serv’s Chief Executive Officer, said, "Our strategic re-alignment and investment is ongoing and our goals are to achieve long-term profitability on our non-performing operations. To that end Europe is a focus for our attention, we have also refocused our US consulting services strategy with a more streamlined business development approach, which has resulted in operational expense savings during the second and third quarters of the current fiscal year…”

Pharma-Bio Serv, Inc. (PBSV), closed Wednesday's trading session at $0.50, even for the day, on 13,799 volume with 3 trades. The average volume for the last 60 days is 26,319 and the stock's 52-week low/high is $0.325/$0.99.

Stony Hill Corp. (STNY)

OTC Markets, MarketWatch, and Market Exclusive reported on Stony Hill Corp. (STNY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Stony Hill Corp. is a diversified enterprise focused on multiple areas of the cannabis, hemp, and CBD industry. The OTCQB-listed Company’s emphasis is on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries. Damian Marley founded the Company. Stony Hill is based in Beverly Hills, California.

The Company has several strategic partnerships now in place. It is actively pursuing additional partnerships and other strategic growth opportunities. Stony Hill’s partners include Ocean Grown Extracts, VitaCBD, and High Times.

Stony Hill has entered into an asset purchase agreement with mCig., Inc. (MCIG). The parties entered into an asset purchase agreement for pursuing mutually beneficial business opportunities in the Cannabidiol (CBD) Industry. With the agreement, mCig sold the VitaCBD brand to Stony Hill in exchange for total consideration of $850,000 in cash and common stock, and also a 20 percent stake in VitaCBD, LLC, a subsidiary of Stony Hill.

Stony Hill made a strategic investment in Cannabi-Tech Ltd earlier this year. The Company acquired the stake in Cannabi-Tech as part of a larger effort to build a global platform and brand for Cannabi-Tech.

Cannabi-Tech is a provider of lab-grade medical cannabis quality control testing systems based in Israel. Its proprietary technology features innovative optical and image processing tools for precise quality control testing of medical marijuana flowers.

Furthermore, Stony Hill has made a strategic investment in High Times Holding Corp. and Precision Cultivation Systems (PCS). With these agreements, Stony Hill will make direct equity investments into High Times Holding and PCS.

Stony Hill is a passive investor. High Times has been the authoritative voice of authentic cannabis culture for over 40 years. The PCS systems features many proprietary features, which help produce healthier plants that consistently delivers increased yield and higher quality flower.

Last month, Stony Hill announced it was expanding its product line and launching a hemp-derived CBD product line under the Stony Hill CBD brand on October 24. 2017. The products will sell on the Company’s new website and in select locations in the United States.

Stony Hill Corp. (STNY), closed Wednesday's trading session at $2.39, down 13.09%, on 5,656 volume with 25 trades. The average volume for the last 60 days is 910 and the stock's 52-week low/high is $0.60/$5.00.

Alexandria Minerals Corp. (ALXDF)

TradingView, MarketWatch, and OTC Markets reported on Alexandria Minerals Corp. (ALXDF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Alexandria Minerals Corp. is a junior gold exploration and development company headquartered in Toronto, Ontario. It has strategic properties situated in the world-class mining districts of Val d'Or, Quebec; Red Lake, Ontario; and Snow Lake-Flin Flon, Manitoba. The Company’s focus is on its flagship property, the large Cadillac Break Property package in Val d'Or, Quebec. Alexandria Minerals’ shares trade on the OTC Markets Group’s OTCQB.

The Cadillac Break Property hosts important, near-surface, gold resources along the prolific, gold-producing Cadillac Break, all of which have considerable growth potential.

The Company’s strategic partnerships are: Agnico-Eagle Mines Limited 9 percent Owners; Teck 2 percent; IAMGOLD Corp., 2 percent; and Funds/High Net Worth Investors 50 percent. Alexandria Minerals’ worldwide gold resources are: Measured and Indicated: 1,400,000 ounces Au; Inferred: 939,200 ounces Au.

Alexandria Minerals has an aggressive exploration program to substantially grow its gold assets. It discovered the Province of Quebec’s next gold mine. In 2014, it sold the West Zone Au-Cu deposit to Agnico Eagle for $5M plus 2 percent NSR and Agnico Eagle filed the environmental application.

Alexandria Minerals had an aggressive exploration program on the Val d’Or Property. It was a 12,500-meter Drill Program. Furthermore, 41,500 meters are planned for completion in April of 2018.

Alexandria Minerals has signed an Option Agreement with Golden Valley Mines. This enables Alexandria to earn 80 percent in the Centremaque Property, located close to its Zone 4 drilling activities. The claims are a strategic addition to the Company’s wholly-owned western Cadillac Break Property Package in Val d'Or, Quebec.

Last week, Alexandria Minerals announced the assay results from 10 holes completed in its detailed summer drill program at Orenada Zone 4 near Val d’Or, Quebec. The reported results further confirm strong gold mineralization east of the Zone 4 open pit over a 250m strike length. The results expand high grade gold mineralization east beyond the limits of the 2009 resource estimate.

Mr. Eric Owens, Alexandria Minerals’ President and Chief Executive Officer, stated, “These exciting results emphasize potential for both growth and grade at Zone 4. We are finding a very robust core area that extends 1,100 metres along strike, down to 300 metres at depth and continues to be open in all directions. Our ongoing geologic and resource modelling efforts are being confirmed and strengthened as results come in. With assay results pending for 70 holes, we expect further great results for the rest of the year.”

Alexandria Minerals Corp. (ALXDF), closed Wednesday's trading session at $0.05, up 3.73%, on 252,500 volume with 13 trades. The average volume for the last 60 days is 136,492 and the stock's 52-week low/high is $0.0253/$0.0725.


The QualityStocks
Company Corner


ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.495, up 1.02%, on 179,908 volume with 50 trades. The stock’s average daily volume over the past 60 days is 106,820 and its 52-week low/high is $0.40/$2.75.

ChineseInvestors.com, Inc. (OTCQB: CIIX) ("CIIX" or the "Company"), the premier financial information website for Chinese-speaking investors, today announced that it has appointed Delray Wannemacher and Patrick Leung as Independent Directors and Keevin Gillespie as an Executive Director effective November 1, 2017. Mr. Wannemacher and Mr. Leung will also serve on the Company's Audit Committee along with its recently appointed Chief Financial Officer, Paul Dickman.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestors.com, Inc. Announces Board of Directors Appointments

ChineseInvestors.com, Inc. (CIIX) Launches New Daily Video Broadcast “Bitcoin Multimillionaire” By Teaming With Wall Street Multimedia, Inc.

ChineseInvestors.com, Inc. Launches Bitcoin Multimillionaire, the First Daily Video Cryptocurrency Newscast in the Chinese Language, With Plans to Launch a New Cryptocurrency Website Under the Domain 'newcoin168.com'

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0628, up 1.45%, on 5,631,475 volume with 439 trades. The stock’s average daily volume over the past 60 days is 15,520,806, and its 52-week low/high is $0.008/$0.415.

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of CNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication, titled, "As Bitcoin Boom Continues, Major Players are Validating Promising Forecasts for its Limitless Value Potential," discusses the seemingly endless climb in bitcoin demand and the companies fighting for their share of the cryptocurrency market. To view the full publication, visit: https://www.cannabisnewswire.com/bitcoin-boom-continues-major-players-validating-promising-forecasts-limitless-value-potential/

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

Podcast Series with Wil Ralston of SinglePoint Talking about Acquisitions, Cannabis and Developments in Cryptocurrency

CannabisNewsWire Announces Publication Highlighting Investment Opportunities in Cryptocurrency

SinglePoint and AppSwarm Sign LOI to Launch Cannabis-Focused Applications

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.34988, off by 1.88%, on 542,842 volume with 290 trades. The stock’s average daily volume over the past 60 days is 520,662, and its 52-week low/high is $0.09/$0.72.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. The publication, titled, "Economic Impact of Biosynthesis on the Cannabis Industry," highlights biotech companies creating cannabis-based products to treat various medical disorders through the development of high-tech extraction methods. To view the full publication, visit: https://www.networknewswire.com/economic-impact-biosynthesis-cannabis-industry/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication Discussing Companies Developing Novel Methods of Extracting Medicinal-Grade Cannabinoids

Economic Impact of Biosynthesis on the Cannabis Industry

NetworkNewsWire Announces Publication Highlighting Innovations in Cannabis R&D

Medical Innovation Holdings, Inc. (MIHI)

The QualityStocks Daily Newsletter would like to spotlight Medical Innovation Holdings, Inc. (MIHI). Today, Medical Innovation Holdings, Inc. closed trading at $0.629, up 25.80%, on 98,833 volume with 52 trades. The stock’s average daily volume over the past 60 days is 42,383, and its 52-week low/high is $0.15/$3.99.

Medical Innovation Holdings, Inc. (MIHI), a Colorado-based publicly traded company, owns and operates strategically aligned healthcare service and product companies focused on the delivery of patient care, management services for physician offices, lab services, and pharma; and non-pharma medicines and alternatives to patients and consumers. Healthcare services are delivered and managed through the company's MSO, 3Point Care. 3Point Care uses virtual telemedicine with a unique customized software and hardware platform as a way of bringing quality medical care to rural and medically underserved areas (MUAs) of the country.

3Point Care provides personalized high-tech, high-touch telemedicine encounters that link virtual health specialty doctors with traditional primary physicians and their patients. This approach helps reduce the cost of care while enhancing the quality of care. The company's telemedicine approach is vastly different from other providers who rely on a monthly subscription to opt in the network and then require an encounter fee by the patient each and every time an on-demand physician is utilized. This approach breaks the continuum of care, relies on symptom-based diagnosis, does not accept insurance, and there is no certainty you are dealing with a licensed practitioner. In summation they are not a medical practice but a contract service to deliver virtual care. Because 3Point Care deploys doctors through an actual medical practice, there is no subscription fee. The company works with anyone and everyone that has insurance including Medicare and Medicaid. It works hand and hand with the patient's primary care physician so the continuum of care is always maintained. Part of the integrated software application enables the processing of insurance claims whereby doctors are paid for their services. This allows deductibles to be captured, allowing the patients to take advantage of medical tax deductions.

TeleLifeMd, a multi-disciplinary specialty healthcare practice with strong experience in telemedicine, is the primary deliverer of patient medical care. 3Point care has a unique and exclusive relationship with TeleLifeMD, acting as its management services organization by providing all levels of service that include scheduling, providing telemedicine hardware and software products and support, processing claims, paying all invoices and payroll incurred by TeleLifeMD, as well as any other service required to operate the practice.

BKare Diagnostics, another wholly owned subsidiary of MIHI, is tasked with delivering medical and health-related services such as laboratory testing, diagnostics, and alternative medicines primarily proven nutraceuticals. Its goal is to eventually infuse these products with 100% CBD/Hemp oil and THC-based oils to create new product categories as the law catches up with the cannabis marketplace. The opportunity to offer workable solutions that solve real health problems outside typical big pharma is very exciting for the company. It sees significant revenue opportunities in this space.

MIHI firmly believes the best way to provide access to high-quality medical care is through support and delivery of evidence-based virtual medicine, commonly known as telemedicine. With 80 million people living in rural, medically underserved areas of the nation, the company is poised to fill a glaring void in the healthcare industry by applying cutting-edge technology and time-tested business practices to deliver real-time care. Among the 16 areas of medical specialties available are cardiology, infertility, gastroenterology, pediatrics and obstetrics.

The company serves a number of constituents and stakeholders interested in reducing the cost of health care while simultaneously increasing the quality of care, improving access to health services for millions of people, and bringing value to company shareholders. Its unique platform incorporates every aspect of a telemedicine visit into a single, comprehensive package. Disclaimer

Medical Innovation Holdings, Inc. Company Blog

Medical Innovation Holdings, Inc. News:

Medical Innovation Holdings to be Featured on National Radio Telecasted Tuesday October 24th, 2017 at 10AM ET on Beasley Broadcasting

NetworkNewsWire Announces Publication Highlighting Innovative Solutions in Telemedicine

Medical Innovation Holdings, Inc. (MIHI) is “One to Watch”

Cache Elite Inc. (ILUS)

The QualityStocks Daily Newsletter would like to spotlight Cache Elite Inc. (ILUS). Today, Cache Elite Inc. closed trading at $0.0124, up 27.84%, on 430,911 volume with 19 trades. The stock’s average daily volume over the past 60 days is 233,057 and its 52-week low/high is $0.0021/$0.065.

Cache Elite Inc. (ILUS) is a forward-thinking technology and service provider. The company provides homeowners with the latest in 3D designs, decorative hardware (http://www.eliteknobs.com), and travel and vacation services. Its foray into travel-related services can be found at the TripWitz website (http://www.tripwitz.com) where its proprietary back-end software, called Internet Travel Management Software, helps TripWitz provide its customers with a distinctive, cost-effective and perfect travel experience that sets it apart from other online travel agencies such as Expedia and Travelocity.

TripWitz provides real-time, dynamically packaged vacation quotes that include airfare, hotels, villas, ground transportation and activities. Every client searching for a smarter way to travel will find TripWitz is able to cut out the stress and frustrations found with other online travel agents. The company provides its intuitive travel services to clients searching vacations possibilities at more than 20,000 destinations around the globe.

TripWitz contracts with over 500,000 hotels and connects with the world's airlines through Google's ITA Gateway software that allows for advanced availability solutions to satisfy millions of queries per second at the lowest possible fares. Seasonal rate fluctuations for many travel services, including ground transportation options, are included in the company's software, giving clients the best possible rates. TripWitz prides itself on giving users a friendly vacation experience that includes access to an experienced vacation destination specialist. Customers are never left to fend for themselves at any point of their vacation experience. TripWitz is also accepting Bitcoins, the international cryptocurrency, as payment for not only flights but vacations as well.

A new report published by Allied Market Research projects the global online travel market will reach an estimated $1,091 billion by 2022, with the Asia-Pacific region expected to witness the highest growth during the forecast period. Travelers are looking for sound help in making travel decisions that fit within their budgets. Younger travelers, those within the 21-31 year age bracket, are seen as a more mobile generation, using social media and smartphones for many of their travel planning and booking needs.

TripWitz is an accredited member of the CCRA (Travel Commerce Network), which connects the company to over 180,000 properties worldwide. TripWitz is also an ARC approval agency. ARC accredited agencies are the most select group of dedicated professionals in the U.S. travel industry and are recognized as having met stringent financial, personnel and security requirements.

The official press release announcing the recent launch of TripWitz can be found at the following link: Cache Elite Inc. (ILUS) Unveils New Venture Into the $341 Billion Travel Industry. Disclaimer

Cache Elite Inc. Blog

Cache Elite Inc. News:

Cache Elite Inc. (ILUS) Engages NetworkNewsWire for Corporate Communications Solutions

Cache Elite Inc. (ILUS) is “One to Watch”

A New Audio Interview with Cache Elite, Inc. CEO, Derrick McWilliams, is now at SmallCapVoice.com

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.49, up 25.61%, on 783,363 volume with 212 trades. The stock’s average daily volume over the past 60 days is 104,530 and its 52-week low/high is $0.1701/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for its DehydraTECH™ Delivery of THC, NSAIDs, Nicotine and Vitamins

NetworkNewsWire Announces Publication Highlighting Recent Developments in Drug Delivery Technologies

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB:PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $1.2786, up 11.80%, on 191,332 volume with 123 trades. The stock’s average daily volume over the past 60 days is 179,049, and its 52-week low/high is $0.4665/$1.54.

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Technologies Inc. Announces Closing of $11.5 Million Bought Deal Offering

Patriot One Technologies Inc. Announces an Increase to the Previously Announced Bought Deal Financing

Patriot One Technologies Inc. Announces $8.5 Million Bought Deal


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(PQEFF) +33.93%


(XNET) +29.56%


(ILUS) +27.84%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251